Holen Sie sich die Stockscreener-App
7.05
0.14%
0.010
Kyntra Bio Inc Aktie (KYNB) Neueste Nachrichten
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status - TipRanks
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - kalkine.ca
Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position - Stock Titan
Kyntra Bio Inc Q2 Net Income From Cont Ops US - Moomoo
KYNB Looks 28.4% Overvalued on GF Value™ - GuruFocus
Kyntra Bio: Q2 Earnings Snapshot - AOL.com
Kyntra Bio Q2 adj. EPS $(4.68) misses $(3.18) estimate - scanx.trade
Kyntra Bio Q2 2026 slides: dual catalysts expected, cash into 2028 - Investing.com
Kyntra Bio Q2 2026 slides: prostate cancer, MDS programs eye Q4 catalysts - Investing.com
Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales - Investing.com
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript - Benzinga
KYNB: Q2 2026 marked clinical progress and a return to profitability, with cash runway into 2028 - TradingView
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kyntra Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KYNTRA BIO ($KYNB) Releases Q2 2026 Earnings - Quiver Quantitative
Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis - GuruFocus
Kyntra Bio (Nasdaq: KYNB) turns Q2 profit as deconsolidation gain offsets cash burn - Stock Titan
Kyntra Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kyntra Bio Targets Late-2026 Milestones for Cancer and Anemia Drugs - Stock Titan
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Kyntra Bio, Inc. expected to post a loss of $3.18 a shareEarnings Preview - TradingView
Earnings Preview: Kyntra Bio to Report Financial Results Post-market on August 13 - 富途牛牛
Kyntra Bio to Report Second Quarter 2026 Financial Results - GlobeNewswire
Kyntra Bio to host a live Q&A after Aug. 13 results - Stock Titan
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
KYNB Q2'26 Earnings: revenue estimate is 2.09M USD - TradingView
Kyntra Bio (KYNB) Holds Steady at $6.79 as Consolidation Builds Toward Key $7.13 TestCall Resistance - dars.gov.et
Kyntra Bio Inc. (KYNB) Holds Steady at $7.0 as Traders Eye Key LevelsAdvance Decline Line - dars.gov.et
Kyntra Bio, Inc. Revenue Breakdown – NASDAQ:KYNB - TradingView
Kyntra Bio, Inc. (KYNB) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
KYNB Stock | Kyntra Bio, Inc. Price, Quote, News & Analysis - TipRanks
Kyntra Bio (KYNB) Shows Strength: Biotech Stock Advances 2.5% as Key Levels Come into PlayDeath Cross - dars.gov.et
Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support ZoneCounter Trend Trade - dars.gov.et
If You Invested $1,000 in KYNTRA BIO INC (KYNB) - Stock Titan
Oppenheimer Maintains Kyntra Bio(KYNB.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35 - Moomoo
KYNB Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer initiates Kyntra Bio stock coverage with outperform rating - Investing.com UK
Oppenheimer initiates Kyntra Bio stock coverage with outperform rating By Investing.com - Investing.com Nigeria
Kyntra Bio Inc. (KYNB) Slides 1.97% as Stock Tests Key Support Near $7.11Time Weighted Price - dars.gov.et
Net margin % of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Kyntra Bio Inc. (KYNB) Edges Higher as Shares Approach Resistance at $8.01Dynamic Hedging - dars.gov.et
KYNB Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineShort-Term Outlook - dars.gov.et
FibroGen stock rises after announcing rebrand to Kyntra Bio By Investing.com - Investing.com Nigeria
Enterprise value to revenue forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Enterprise value to EBITDA forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to earnings forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to sales forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to book forward of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
KYNB Forecast — Price Target — Prediction for 2027 - TradingView
0IL8 Forecast — Price Target — Prediction for 2027 - TradingView
Kyntra Bio, Inc. Actuals & Estimates (NASDAQ:KYNB) - TradingView
Enterprise value to EBIT forward of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
Price to book forward of Kyntra Bio, Inc. – TRADEGATE:1FG0 - TradingView
1FG0 Forecast — Price Target — Prediction for 2027 - TradingView
Kyntra Bio Inc. (KYNB) Edges Higher on Above-Average Volume, Tests Key Resistance ZoneMotive Wave - dars.gov.et
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D Spending - dars.gov.et
Kyntra Bio, Inc. Statistics – DUS:1FG0 - TradingView
Basic earnings per share (basic EPS) of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):